National epidemiology of mycoses survey: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 1, 1998, Pages 289-296

  Pfaller, M A ^a   Messer, S A ^a   Houston, A ^a   Rangel Frausto, M S ^a   Wiblin, T ^a   Blumberg, H M ^b   Edwards, J E ^c   Jarvis, W ^b,d   Martin, M A ^e   Neu, H C ^f   Saiman, L ^f   Patterson, J E ^g   Dibb, J C ^g   Roldan, C M ^g   Rinaldi, M G ^g   Wenzel, R P ^h  

^a UNIVERSITY OF IOWA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Howard Hughes Medical Institute   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ABSCESS; ADULT; ARTICLE; BLOOD; CANDIDA; CLINICAL TRIAL; DNA DETERMINATION; DRUG SENSITIVITY; FUNGUS IDENTIFICATION; HEALTH CARE PERSONNEL; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KARYOTYPE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOSIS; NEWBORN; NEWBORN INTENSIVE CARE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SAMPLING; TECHNIQUE; TISSUE; WOUND INFECTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HEALTH SURVEYS; HUMANS; INTENSIVE CARE UNITS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 0031899842     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00245-9     Document Type: Article

References (24)

1. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ. Secular trends in nosocomial primary blood stream infections in the United States, 1980-1989. Am J Med. 91:(suppl 3B):1991;86S-89S.
2. Beck-Sague CM, Jarvis WR. National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 167:1993;1247-1251.
3. Berrouane YF, Hollis RJ, Pfaller MA. Strain variation and antifungal susceptibilities among isolates of Candida krusei. J Clin Microbiol. 34:1996;1856-1858.
4. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 6:1993;428-442.
5. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis an epidemic of the 1980s . Clin Infect Dis. 21:1995;897-904.
6. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 9:1996;499-511.
7. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Cont. 16:1988;128-140.
8. Hollis RJ, Doebbeling BN, Pfaller MA. Restriction endonuclease analysis of genomic DNA from Candida species. Maresca B, Kobayashi GS. Molecular Biology of Pathogenic Fungi A Laboratory Manual . 1995;Springer-Verlag, New York.
9. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 20:1995;1526-1530.
10. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts Approved Standard. NCCLS Document 27-A . 1997;NCCLS, Wayne, PA.
11. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL. The changing face of candidemia emergence of non-Candida albicans species and antifungal resistance . Am J Med. 100:1996;617-623.
12. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect. 30:(suppl):1995;329-338.
13. Pfaller MA. Epidemiology of fungal infections current perspectives and future directions . Clin Infect Dis. 20:1995;1525.
14. Pfaller MA. Nosocomial candidiasis emerging species, reservoirs, and modes of transmission . Clin Infect Dis. 22:(suppl 2):1996;S89-S94.
15. Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG, Cooper CR, McGinnis MR. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J Clin Microbiol. 33:1995;1104-1107.
16. Pfaller MA, Cabezudo I, Koontz F, Bale M, Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol. 6:1987;628-633.
17. Pfaller MA, Hollis RJ, Sader HS. Chromosomal restriction fragment analysis by pulsed-field gel electrophoresis. Isenberg HD. Clinical Microbiology Procedures Handbook, Suppl 1. 1994;American Society for Microbiology, Washington, DC.
18. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL. Trends in infectious diseases mortality in the United States. J Am Med Assoc. 275:1996;189-193.
19. Pittet D, Wenzel RP. Nosocomial blood stream infections. Arch Intern Med. 155:1995;1177-1184.
20. Strausbaugh LJ, Sewell DL, Tjoelker RC, Heitzman T, Webster T, Ward TT, Pfaller MA. Comparison of three methods for recovery of yeasts from hands of health-care workers. J Clin Microbiol. 34:1996;471-473.
21. Warren NG, Hazen KC. Candida, Cryptococcus, and other yeasts of medical importance. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of Clinical Microbiology. 1995;723-737 American Society for Microbiology, Washington, DC.
22. Wenzel RP. Nosocomial candidemia Risk factors and attributable mortality . Clin Infect Dis. 20:1995;1531-1534.
23. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia The attributable mortality and excess length of stay . Arch Intern Med. 148:1988;2642-2645.
24. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. Arch Intern Med. 149:1989;2349-2353.